BIOMERIEUX: directors' dealings · France · AMF

About BIOMERIEUX

bioMérieux is a global benchmark in in vitro diagnostics, providing solutions that detect, identify and monitor infectious agents as well as other disease states. Founded in 1963 in Marcy-l’Étoile, near Lyon, within the industrial and scientific ecosystem established by the Mérieux family, the company was built around a long-term mission: improving public health through fast, reliable and accessible diagnostic tools. As a family-controlled listed company, bioMérieux has gradually expanded into a leading position across several diagnostic segments, supported by an extensive international commercial and industrial footprint. The group’s business model is anchored in four main pillars: microbiology, syndromic testing, industrial applications and point-of-care diagnostics. In microbiology, bioMérieux provides instruments, reagents and consumables used by hospital and private laboratories to analyze infections and antimicrobial resistance. In syndromic diagnostics, the BIOFIRE® platform enables the rapid identification of multiple pathogens from a single sample. The company also develops solutions for the food, pharmaceutical and cosmetics industries to help secure production lines and ensure microbiological quality control. Its portfolio also includes SPOTFIRE®, a point-of-care platform designed for decentralized testing and faster clinical decision-making. bioMérieux is widely recognized as a global leader in in vitro diagnostics, with particularly strong positioning in clinical microbiology and a meaningful presence in syndromic testing. In 2024, the company generated €3.98 billion in sales, delivering 10.3% organic growth, driven by BIOFIRE®, the ramp-up of SPOTFIRE® and resilient performance in microbiology. For fiscal year 2025, sales reached €4.07 billion, confirming the group’s ability to sustain profitable growth. The company operates worldwide, with activities across Europe, North America, Latin America and Asia-Pacific. Headquartered in Marcy-l’Étoile, bioMérieux relies on a global network of manufacturing sites, R&D centers and sales subsidiaries. Recent milestones include the accelerated rollout of SPOTFIRE®, targeted acquisitions aimed at strengthening rapid diagnostics capabilities, and the company’s presence in major French and European equity indices, reflecting both its scale and market visibility.